CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for acute myeloid leukemia (AML). However, most patients experience relapse after allo-HSCT, with a poor prognosis, and treatment options are limited. The lack of an ideal targetable antigen i...

Full description

Bibliographic Details
Main Authors: Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Wei Cui, Baoquan Song, Jia Yin, Zheng Li, Xiaming Zhu, Changju Qu, Tianhui Liu, Wenhong Shen, Mingqing Zhu, Lei Yu, Depei Wu, Xiaowen Tang
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Journal of Hematology & Oncology
Subjects:
Chimeric antigen receptor T cells
CAR-T-38
Relapsed acute myeloid leukemia
Allogeneic hematopoietic stem cell transplantation
Cytokine release syndrome
Online Access:https://doi.org/10.1186/s13045-021-01092-4

Internet

https://doi.org/10.1186/s13045-021-01092-4

Similar Items